Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 11.17M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.42M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 84.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 131.45M | 52W Low Chg | 431.00% |
| Insider Own | 81.01% | ROA | -96,214.64% | Shares Float | 24.97M | Beta | 0.95 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.09 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 12,179 | Target Price | - |
| Oper. Margin | - | Earnings Date | Oct 10 | Volume | 125 | Change | 0.00% |
About BURZYNSKI RESEARCH INSTITUTE IN
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was incorporated in 1984 and is headquartered in Houston, Texas.